Stock listing
Stuttgart:EU6 PDS Biotechnology Corporation Aktie
German listing (Stuttgart) of PDS Biotechnology Corporation · home listing NASDAQ:PDSB
Follow PDS Biotechnology Corporation into a list and get an email when it puts out news.
Home listing price · NASDAQ:PDSB
$0.777 USD -0.007 (-0.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PDSB
- Day range
- $0.770 – $0.845 USDNov 20, 2026
- Volume
- 2.89M sharesNov 20, 2026
- Market cap
- $95.39M USDAt the close on Nov 20, 2026 · price × 122.7M shares outstanding
- 52-week range
- $0.195 – $1.790 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.04M USDMedian day 4.88M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PDSB · Home | $0.777 USD | -0.007 (-0.9%) | 2,893,951 | $0.800 | $0.845 | $0.770 | $0.784 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PDSB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.777 | -0.007 | -0.9% | $0.800 | $0.845 | $0.770 | 2,893,951 | |
| $0.784 | -0.110 | -12.3% | $0.907 | $0.921 | $0.762 | 4,262,607 | |
| $0.894 | -0.030 | -3.3% | $0.925 | $0.980 | $0.888 | 3,507,932 | |
| $0.924 | +0.051 | +5.9% | $0.809 | $0.969 | $0.809 | 5,249,300 | |
| $0.873 | -0.107 | -11.0% | $0.990 | $0.990 | $0.750 | 5,925,095 | |
| $0.980 | -0.040 | -3.9% | $0.970 | $1.020 | $0.920 | 2,882,877 | |
| $1.020 | -0.010 | -1.0% | $1.040 | $1.050 | $0.980 | 2,824,770 | |
| $1.030 | -0.050 | -4.6% | $1.015 | $1.050 | $0.944 | 4,284,014 | |
| $1.080 | -0.150 | -12.2% | $1.160 | $1.160 | $1.020 | 4,073,436 | |
| $1.230 | +0.060 | +5.1% | $1.190 | $1.270 | $1.174 | 2,923,610 | |
| $1.170 | -0.130 | -10.0% | $1.280 | $1.285 | $1.130 | 3,565,467 | |
| $1.300 | -0.110 | -7.8% | $1.470 | $1.478 | $1.270 | 4,550,142 | |
| $1.410 | +0.040 | +2.9% | $1.350 | $1.530 | $1.350 | 5,116,347 | |
| $1.370 | -0.070 | -4.9% | $1.485 | $1.485 | $1.315 | 4,122,044 | |
| $1.440 | -0.110 | -7.1% | $1.490 | $1.550 | $1.330 | 5,391,417 | |
| $1.550 | +0.030 | +2.0% | $1.530 | $1.700 | $1.520 | 8,105,687 | |
| $1.520 | +0.220 | +16.9% | $1.290 | $1.605 | $1.280 | 15,086,505 | |
| $1.300 | +0.235 | +22.1% | $1.060 | $1.390 | $1.040 | 10,597,699 | |
| $1.065 | -0.045 | -4.1% | $1.100 | $1.100 | $1.033 | 2,244,136 | |
| $1.110 | -0.050 | -4.3% | $1.110 | $1.130 | $1.060 | 2,700,300 | |
| $1.160 | -0.080 | -6.5% | $1.160 | $1.220 | $1.115 | 5,122,600 | |
| $1.240 | +0.279 | +29.0% | $0.998 | $1.310 | $0.990 | 15,240,000 | |
| $0.961 | +0.044 | +4.8% | $0.930 | $0.986 | $0.900 | 4,092,800 | |
| $0.917 | -0.213 | -18.8% | $1.130 | $1.140 | $0.917 | 8,424,400 | |
| $1.130 | -0.170 | -13.1% | $1.250 | $1.260 | $1.090 | 6,935,800 | |
| $1.300 | -0.110 | -7.8% | $1.371 | $1.390 | $1.095 | 10,232,700 | |
| $1.410 | -0.190 | -11.9% | $1.600 | $1.670 | $1.380 | 9,457,700 | |
| $1.600 | +0.080 | +5.3% | $1.430 | $1.790 | $1.390 | 16,967,400 | |
| $1.520 | +0.140 | +10.1% | $1.485 | $1.550 | $1.380 | 15,076,400 | |
| $1.380 | +0.360 | +35.3% | $1.040 | $1.400 | $1.000 | 16,062,000 | |
| $1.020 | -0.045 | -4.2% | $1.040 | $1.100 | $0.960 | 4,875,800 | |
| $1.065 | +0.020 | +1.9% | $1.050 | $1.100 | $1.000 | 5,604,600 | |
| $1.045 | -0.155 | -12.9% | $1.150 | $1.270 | $0.936 | 17,042,600 | |
| $1.200 | +0.451 | +60.2% | $0.781 | $1.350 | $0.769 | 78,550,900 | |
| $0.749 | +0.043 | +6.1% | $0.715 | $0.750 | $0.709 | 3,656,800 | |
| $0.706 | -0.045 | -6.0% | $0.750 | $0.760 | $0.700 | 3,726,200 | |
| $0.751 | +0.008 | +1.1% | $0.724 | $0.761 | $0.710 | 4,585,600 | |
| $0.743 | -0.023 | -3.0% | $0.751 | $0.770 | $0.729 | 2,706,400 | |
| $0.766 | -0.031 | -3.9% | $0.781 | $0.790 | $0.728 | 4,042,400 | |
| $0.797 | -0.003 | -0.4% | $0.804 | $0.822 | $0.781 | 3,937,400 | |
| $0.800 | -0.024 | -2.9% | $0.810 | $0.810 | $0.750 | 6,097,400 | |
| $0.824 | -0.086 | -9.5% | $0.880 | $0.906 | $0.818 | 9,724,200 | |
| $0.910 | +0.068 | +8.1% | $0.860 | $0.995 | $0.812 | 24,750,000 | |
| $0.842 | +0.036 | +4.5% | $0.937 | $0.970 | $0.807 | 17,073,200 | |
| $0.806 | -0.036 | -4.3% | $0.823 | $0.900 | $0.751 | 18,976,900 | |
| $0.842 | -0.149 | -15.0% | $0.908 | $0.998 | $0.820 | 35,878,100 | |
| $0.991 | +0.406 | +69.4% | $0.649 | $1.060 | $0.620 | 196,516,300 | |
| $0.585 | +0.186 | +46.6% | $0.492 | $0.755 | $0.413 | 372,179,900 | |
| $0.399 | +0.104 | +35.3% | $0.278 | $0.450 | $0.261 | 80,847,300 | |
| $0.295 | -0.020 | -6.3% | $0.320 | $0.320 | $0.293 | 5,839,200 | |
| $0.315 | +0.022 | +7.5% | $0.291 | $0.330 | $0.285 | 12,732,500 | |
| $0.293 | -0.007 | -2.3% | $0.300 | $0.318 | $0.285 | 19,253,100 | |
| $0.300 | +0.080 | +36.4% | $0.488 | $0.651 | $0.257 | 491,124,600 | |
| $0.220 | 0.000 | 0.0% | $0.220 | $0.238 | $0.217 | 1,083,600 | |
| $0.220 | +0.008 | +3.8% | $0.215 | $0.230 | $0.207 | 832,600 | |
| $0.212 | +0.008 | +3.9% | $0.201 | $0.218 | $0.201 | 765,000 | |
| $0.204 | -0.010 | -4.7% | $0.210 | $0.210 | $0.197 | 591,500 | |
| $0.214 | +0.003 | +1.4% | $0.210 | $0.232 | $0.206 | 1,353,300 | |
| $0.211 | -0.007 | -3.2% | $0.215 | $0.225 | $0.208 | 837,700 | |
| $0.218 | -0.005 | -2.2% | $0.224 | $0.234 | $0.214 | 1,242,800 | |
| $0.223 | +0.002 | +0.7% | $0.223 | $0.226 | $0.215 | 1,197,600 | |
| $0.222 | +0.005 | +2.2% | $0.219 | $0.229 | $0.217 | 1,185,908 | |
| $0.217 | -0.002 | -1.0% | $0.219 | $0.222 | $0.207 | 697,412 | |
| $0.219 | +0.010 | +4.8% | $0.208 | $0.236 | $0.208 | 2,933,100 | |
| $0.209 | +0.008 | +4.0% | $0.203 | $0.218 | $0.198 | 2,008,700 |
Splits
1 split · NASDAQ:PDSB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- Stuttgart:EU6
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
PDS Biotech Reports Third Quarter 2026 Financial Results
Latest earnings call · May 13, 2026
PDS Biotechnology (NASDAQ:PDSB) Q1 2026 Earnings Call
Replay and transcript
Latest deck · Oct 21, 2026
Investor Presentation (October 2026)
Investor deck · 28 slides
Latest news
PDS Biotech Reports Third Quarter 2026 Financial Results
Nov 13, 2026
Closed $0.873 (-11.0%) on Nov 13, 2026
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
Nov 10, 2026
Closed $1.03 (-4.6%) on Nov 10, 2026
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
Oct 20, 2026
Closed $0.961 (+4.8%) on Oct 20, 2026
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
Oct 6, 2026
Closed $1.05 (-12.9%) on Oct 6, 2026
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
Sep 22, 2026
Closed $0.91 (+8.1%) on Sep 22, 2026
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Sep 14, 2026
Closed $0.399 (+35.3%) on Sep 14, 2026
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Sep 8, 2026
Closed $0.30 (+36.4%) on Sep 8, 2026
PDS Biotech Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Closed $0.233 (-3.7%) on Aug 13, 2026
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Aug 11, 2026
Closed $0.257 (-64.8%) on Aug 11, 2026
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
May 13, 2026
Closed $1.33 (+20.9%) on May 13, 2026
PDS Biotechnology Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 236 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest May 13, 2026
- Decks
- 90 decks · latest Oct 21, 2026
Where PDS Biotechnology Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PDSB · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2PF3F | LS Exchange | Germany | EUR |
| gettex:EU6 | gettex | Germany | EUR |
| Lang & Schwarz:A2PF3F | Lang & Schwarz | Germany | EUR |
| Tradegate:EU6 | Tradegate | Germany | EUR |
| BOATS:PDSB | BOATS | United States | USD |
| Frankfurt:EU6 | Frankfurt | Germany | EUR |
| Dusseldorf:EU6 | Dusseldorf | Germany | EUR |
| Hamburg:EU6 | Hamburg | Germany | EUR |
| Munich:EU6 | Munich | Germany | EUR |
| Stuttgart:EU6 · This page | Stuttgart | Germany | EUR |
Valuation
Price/book 7.1× against a median of 1.9×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $80.15M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 7.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.04
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corporation · NASDAQ:PDSB | US$95.39M | US$80.15M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | 2.04 |
| Unicycive Therapeutics, Inc. · NASDAQ:UNCY | US$97.77M | US$39.32M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.09 |
| NovaBridge Biosciences · NASDAQ:NBP | US$96.28M | US$68.30M | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 1.37 |
| Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496 | US$96.17M | US$105.6M | n/a | 7.8× | n/a | n/a | −53.2% | n/a | n/a |
| Immunic, Inc. · NASDAQ:IMUX | US$95.37M | −US$36.09M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.51 |
| NRX Pharmaceuticals, Inc. · NASDAQ:NRXP | US$95.31M | US$76.46M | n/a | 17.7× | n/a | n/a | −458.5% | n/a | 2.23 |
| Allergy Therapeutics plc · LSE:AGY | US$95.27M | US$117.1M | n/a | 1.6× | n/a | 17.1× | −72.9% | 6.3× | n/a |
| Voyager Therapeutics, Inc. · NASDAQ:VYGR | US$95.21M | −US$11.60M | n/a | −0.5× | n/a | 0.7× | −416.3% | 0.0× | 1.45 |
| Outlook Therapeutics, Inc. · NASDAQ:OTLK | US$94.94M | US$83.70M | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Molecular Partners AG · SIX:MOLN | US$93.53M | −US$4.92M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Sunhawk Vision Biotech, Inc. · TPEX:7759 | US$93.04M | US$82.43M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| Median of the others | US$95.29M | US$72.38M | 4.7× | 1.9× | −244.6% | 0.0× | 1.41 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.44 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Frank Bedu-Addo | Chief Executive Officer, Director |
| James Banaag | Senior Vice President Finance, Corporate Strategy, Chief Financial Officer |
| Spencer Brown | Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer |
| Gregory Conn | Chief Scientific Officer |
| Kirk Shepard | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Bruce Wendel | Director |
| Deborah Ramsdell | Director |
| Frank Bedu-Addo | Chief Executive Officer, Director |
| Ilian Iliev | Director |
| James Banaag | Senior Vice President Finance, Corporate Strategy, Chief Financial Officer |
| John Dawson | Director |
| Patrick Soon-Shiong | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| PDS Biotechnology (NASDAQ:PDSB) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q4 2025 Earnings Call | Mon, Mar 30, 2026 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:30 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q4 2023 Earnings Call | Wed, Mar 27, 2024 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| PDS Biotechnology (NASDAQ:PDSB) Q1 2023 Earnings Call | Mon, May 15, 2023 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q4 2022 Earnings Call | Tue, Mar 28, 2023 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q1 2022 Earnings Call | Wed, May 11, 2022 · 11:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q4 2021 Earnings Call | Thu, Mar 31, 2022 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 8:00 AM ET | Replay |
| PDS Biotechnology (NASDAQ:PDSB) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | −11.0% |
| Q2 2026 | Aug 13, 2026 · Before open | −3.7% |
| Q1 2026 | May 13, 2026 · Before open | +20.9% |
| Q4 2025 | Mar 26, 2026 | −14.7% |
| Q3 2025 | Nov 13, 2025 · After close | −0.5% |
| Q2 2025 | Aug 13, 2025 · Before open | −5.7% |
| Q1 2025 | May 14, 2025 · Before open | +3.1% |
| Q4 2024 | Mar 25, 2025 · Before open | −3.6% |
| Q3 2024 | Nov 14, 2024 · Before open | −18.3% |
| Q2 2024 | Aug 13, 2024 · Before open | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −1.0% |
| Q4 2023 | Mar 27, 2024 · Before open | −14.1% |
| Q3 2023 | Nov 14, 2023 · Before open | +18.6% |
| Q2 2023 | Aug 14, 2023 · After close | +10.3% |
| Q1 2023 | May 15, 2023 · Before open | +7.4% |
| Q4 2022 | Mar 28, 2023 · Before open | +3.0% |
| Q3 2022 | Nov 14, 2022 · Before open | +26.1% |
| Q2 2022 | Aug 8, 2022 · Before open | −2.3% |
| Q1 2022 | May 11, 2022 · Before open | −15.9% |
| Q4 2021 | Mar 31, 2022 · Before open | −1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 28 slides | Oct 21, 2026 |
| Investor Presentation (September 2026) | Investor deck | 28 slides | September 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 13, 2026 |
| Investor Presentation (April 2026) | Investor deck | 21 slides | Apr 24, 2026 |
| Investor Presentation (February 2026) | Investor deck | 22 slides | Feb 23, 2026 |
| Investor Presentation (February 2026) | Investor deck | 22 slides | February 2026 |
| Investor Presentation (August 2025) | Investor deck | 22 slides | Aug 25, 2025 |
| Investor Presentation (August 2025) | Investor deck | 22 slides | August 2025 |
| Investor Presentation (June 2025) | Investor deck | 23 slides | Jun 25, 2025 |
| Investor Presentation (June 2025) | Investor deck | 23 slides | June 2025 |
Show 50 decks
This page holds 50 of 90 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock warrants (common stock or pre-funded warrants) Closed: US$3.9M raised · US$0.22 a share Buyers: NantWorks (exercised warrants to purchase an aggregate of 17,699,115 shares (or pre-funded warrants in lieu thereof)) Use of proceeds: Advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, PDS0101 partnership strategy and general corporate purposes | Nov 10, 2026 |
| Private placement of units of common stock or pre-funded warrants with common warrants Tranche closed: US$11.3M raised · US$0.2825 a unit · a Common Warrant to purchase one-half of one Private Placement Share Buyers: Nant Capital, LLC (Led the round; obligated to purchase $10,000,000 at the Milestone Closing); AB Group Ltd. (Obligated to purchase $1,000,000 at the Milestone Closing) Use of proceeds: Repay outstanding indebtedness, working capital and general corporate purposes, including clinical development, R&D and G&A expenses | Sep 14, 2026 |
| Registered direct offering of shares of common stock (or pre-funded warrants) and accompanying warrants Announced: about US$5.3M · US$0.91 a share · Warrants at US$1 for 60 months · Craig-Hallum Dealers: Craig-Hallum (lead) Use of proceeds: Continuation of the VERSATILE-003 Phase 3 trial, other research and development and general corporate purposes | Nov 11, 2025 |
| Registered direct offering of shares of common stock (or common stock equivalents) and warrants Announced: about US$11M · US$1.5 a share · Warrants at US$1.5 for 60 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Insiders: Certain directors of the Company participate at a combined purchase price of $1.66 Use of proceeds: Research and development expenses and general corporate purposes | Feb 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Edge Therapeutics, Inc. Priced at US$11.00 a share on Sep 30, 2015.
- Price
- US$11.00 a share
- Shares offered
- 7,315,151 shares of common stock
- Offering size
- US$80.5 million
- Underwriters' option
- Up to 1,097,272 more shares
- Underwriters
- Leerink Partners, Credit Suisse, Guggenheim Securities, JMP Securities · In the order on the cover
- Shares delivered
- On or about Oct 6, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 21, 2014 |
| Filed publicly | Aug 14, 2015 |
| Amended once | Sep 21, 2015 |
| Shares registered with an exchange | Sep 25, 2015 |
| Declared effective by the SEC | Sep 30, 2015 |
| Final prospectus, with the price | Oct 2, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 2, 2015 |
| EFFECT · Notice that a registration is effective | Sep 30, 2015 |
| S-1MEF · Registration of more shares for the same offering | Sep 30, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Sep 30, 2015 |
| CORRESP · Letter to the SEC | Sep 28, 2015 |
| CORRESP · Letter to the SEC | Sep 28, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 25, 2015 |
| S-1/A · Registration statement, amended | Sep 21, 2015 |
| CORRESP · Letter to the SEC | Sep 14, 2015 |
| CORRESP · Letter to the SEC | Aug 14, 2015 |
All 26 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Aug 14, 2015 |
| UPLOAD · Letter from the SEC | Jun 10, 2015 |
| DRSLTR · Letter to the SEC with a draft | May 20, 2015 |
| DRS/A · Draft registration statement, amended | May 20, 2015 |
| UPLOAD · Letter from the SEC | Dec 18, 2014 |
| DRSLTR · Letter to the SEC with a draft | Dec 4, 2014 |
| DRS/A · Draft registration statement, amended | Dec 4, 2014 |
| UPLOAD · Letter from the SEC | Sep 26, 2014 |
| DRS/A · Draft registration statement, amended | Sep 10, 2014 |
| DRSLTR · Letter to the SEC with a draft | Jul 10, 2014 |
| DRS/A · Draft registration statement, amended | Jul 10, 2014 |
| UPLOAD · Letter from the SEC | Jun 6, 2014 |
| DRSLTR · Letter to the SEC with a draft | May 19, 2014 |
| DRS/A · Draft registration statement, amended | May 19, 2014 |
| UPLOAD · Letter from the SEC | Apr 18, 2014 |
| DRS · Draft registration statement | Mar 21, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 2, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 60.5K | 59.8K | 57.3K | 49.1K | 246.4K | 176.3K | 98.4K | 69.1K | 182.9K | 100.1K |
| Gross profit | -60.5K | -59.8K | -57.3K | -49.1K | -246.4K | -176.3K | -98.4K | -69.1K | -183.0K | -100.0K |
| Research and development | 19.0M | 22.6M | 27.8M | 29.4M | 11.3M | 7.92M | 6.10M | 830.7K | 34.3M | 24.8M |
| Selling, general and administrative | 12.5M | 13.5M | 15.0M | 12.2M | 10.2M | 6.79M | 11.0M | 14.3M | 17.7M | 14.7M |
| Operating income | -31.5M | -36.3M | -43.0M | -41.7M | -21.4M | -14.9M | -21.0M | -3.65M | -52.0M | -39.5M |
| Depreciation and amortization | 21.8K | 21.1K | 17.4K | 86 | 5.36K | 15.6K | 98.4K | 69.1K | 182.9K | 100.1K |
| EBITDA | -31.5M | -36.3M | -43.0M | -41.7M | -21.4M | -14.9M | -20.9M | -3.58M | -51.8M | -39.4M |
| Interest expense | 5.34M | 4.67M | 4.21M | 1.32M | 0 | 0 | 33.6K | 3.60K | 2.18M | 1.20M |
| Income before tax | -35.7M | -38.5M | -44.3M | -42.1M | -21.4M | -14.8M | -7.38M | -3.84M | -53.4M | -40.7M |
| Income tax | -1.17M | -869.2K | -1.41M | -1.20M | -4.52M | 0 | -381.5K | 0 | -2.59M | -1.85M |
| Net income | -34.5M | -37.6M | -42.9M | -40.9M | -16.9M | -14.8M | -7.00M | -3.84M | -50.9M | -38.8M |
| Earnings per share, basic | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | 1.15 | -1.65 | -1.34 |
| Earnings per share, diluted | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | 1.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.7M | 41.7M | 56.6M | 73.8M | 65.2M | 28.8M | 12.2M | 103.7K | 88.1M | 106.4M |
| Receivables | 3.90K | 13.5K | ||||||||
| Current assets | 28.3M | 45.1M | 59.1M | 76.5M | 66.8M | 30.3M | 14.5M | 122.1K | 89.1M | 107.4M |
| Property, plant and equipment | 120.2K | 142.0K | 134.1K | 0 | 86 | 5.44K | 21.1K | 29.5K | 3.42M | 3.42M |
| Total assets | 30.5M | 45.4M | 59.4M | 77.0M | 67.2M | 30.9M | 14.5M | 164.4K | 92.6M | 110.9M |
| Accounts payable | 3.57M | 1.68M | 6.98M | 1.22M | 1.31M | 1.42M | 1.20M | 1.31M | 4.37M | 3.47M |
| Current liabilities | 9.48M | 17.1M | 13.6M | 9.82M | 3.76M | 3.27M | 2.79M | 1.91M | 12.9M | 6.68M |
| Long-term debt | 11.7M | 9.20M | 19.5M | 23.0M | 30.0K | 17.4M | 15.0M | |||
| Total debt | 16.9M | 21.8M | 23.9M | 23.5M | 490.4K | 610.3K | 30.0K | 20.5M | 15.0M | |
| Total liabilities | 21.2M | 26.4M | 33.3M | 33.0M | 3.99M | 3.76M | 2.79M | 2.23M | 30.2M | 21.6M |
| Shareholders' equity | 9.25M | 19.0M | 26.1M | 44.0M | 63.2M | 27.1M | 11.7M | -2.07M | -609.5K | 89.3M |
| Shares outstanding | 54.9M | 38.0M | 33.1M | 30.2M | 28.4M | 22.3M | 5.28M | 3.42M | 30.9M | 28.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -27.8M | -35.0M | -33.6M | -25.7M | -12.5M | -13.1M | -18.1M | -1.57M | -40.7M | -32.2M |
| Capital spending | 0 | -29.0K | 0 | -4 | -4 | -5 | -1 | 0 | -188.7K | -686.7K |
| Free cash flow | -27.8M | -35.1M | -33.6M | -25.7M | -12.5M | -13.1M | -18.1M | -1.57M | -40.9M | -32.9M |
| Cash from investing | 0 | -29.0K | 0 | 0 | 29.4M | 0 | -188.7K | -686.7K | ||
| Cash from financing | 12.8M | 20.2M | 16.4M | 34.3M | 48.9M | 29.8M | 750.0K | 1.50M | 22.6M | 9.08M |
| Dividends paid | -271 | |||||||||
| Share buybacks | -271 | 29.8M | 750.0K | 721.2K | 17.6M | 315.0K | ||||
| Change in cash | -15.0M | -14.9M | -17.3M | 8.58M | 36.4M | 16.7M | 12.1M | -53.4M | -18.3M | -23.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Nov 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 20, 2026 | Management or board change | SEC |
| S-3 · Registration statement | Oct 14, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 21, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 14, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 8, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 4, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 19, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 14, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 22, 2026 | Other filings | SEC |
| 424B4 · Prospectus | Jul 21, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jul 10, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Jun 26, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 26, 2026 | Meeting notice | SEC |
| 424B5 · Prospectus | Jun 15, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Jun 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 15, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 8-K · Current report | May 1, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 29, 2026 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2026 | Annual report | SEC |
| S-3/A · Registration statement, amended | Apr 27, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 24, 2026 | Current report | SEC |
| 8-K · Current report | Apr 15, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| 8-K · Current report | Feb 20, 2026 | Current report | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 9, 2025 | Current report | SEC |
| 8-K · Current report | Dec 2, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jun 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 6, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 30, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 27, 2025 | Offer document | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| DEFR14A | May 22, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| DEFR14A | May 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 2, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 8-K · Current report | Mar 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 28, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 28, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Oct 2, 2024 | Current report | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 13, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| 8-K · Current report | Aug 7, 2024 | Current report | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 8-K · Current report | Aug 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | May 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2024 | Insider trade | SEC |
| 8-K · Current report | May 2, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| 8-K · Current report | Mar 13, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 4, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 4, 2023 | Current report | SEC |
| 8-K · Current report | Nov 28, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 8-K · Current report | Oct 11, 2023 | Current report | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 2, 2023 | Current report | SEC |
| 8-K · Current report | Sep 20, 2023 | Current report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Aug 18, 2023 | Current report | SEC |
| 8-K · Current report | Aug 17, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 25, 2023 | Current report | SEC |
| 4 · Change in ownership | Jul 17, 2023 | Insider trade | SEC |
This page holds 200 of 806 filings. Open Filings
Cap table
Built by 6ix from PDS Biotechnology Corporation’s releases · as of Nov 10, 2026
- Common shares
- 122,704,544
- Fully diluted
- 130,955,979
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 122,704,544 | |
| Warrants | 8,251,435 | Sep 11, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 122,704,544 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Liam Ratcliffe Other companies: OnKure Therapeutics, Inc. (Director · Since at least Mar 27, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Climb Bio, Inc. (Director · Aug 9, 2021 – Jun 26, 2024 · Past); Passage Bio, Inc. (Director · Feb 27, 2020 – May 27, 2021 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 29, 2019 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – May 17, 2018 · Past) | Director · Jun 21, 2016 – Mar 15, 2019 · Past |
| Sol J. Barer Other companies: Teva Pharmaceutical Industries Limited (Director · Since at least Jan 1, 2018); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); CervoMed Inc. (Director · Nov 1, 2013 – Jul 24, 2014 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past) | Director · Sep 30, 2015 – Mar 15, 2019 · Past |
| Isaac Blech Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past) | Director · Sep 30, 2015 – Mar 15, 2019 · Past |
| Robert J. Spiegel Other companies: Ernexa Therapeutics Inc. (Director · Since at least Sep 14, 2026); RenovoRx, Inc. (Director · Since at least Apr 25, 2023); Geron Corporation (Director · Since at least Sep 29, 2017); Athenex Inc (Director · Aug 4, 2020 – Apr 21, 2023 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Bio Green Med Solution, Inc. (Director · Sep 6, 2018 – Jun 30, 2023 · Past); Sucampo Pharmaceuticals Inc (Director · Feb 13, 2018 – Feb 13, 2018 · Past) | Director · Jun 19, 2018 – Mar 15, 2019 · Past |
| Andrew Saik Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); Arvinas, Inc. (Chief Financial Officer and Treasurer · Since at least Jun 24, 2024); Intercept Pharmaceuticals Inc (EVP & Chief Financial Officer · Jun 21, 2021 – Nov 8, 2023 · Past); VYNE Therapeutics Inc. (Chief Financial Officer · Sep 8, 2020 – May 28, 2021 · Past); Auxilium Pharmaceuticals Inc (CFO · Aug 18, 2014 – Jan 29, 2015 · Past) | Chief Financial Officer, Director · Oct 31, 2017 – Feb 14, 2020 · Past |
| Patrick Soon-Shiong Other companies: ImmunityBio, Inc. (Executive Chairman of the Board · Since at least Jul 27, 2015); tronc Inc (Director · Nov 4, 2016 – Mar 20, 2017 · Past); Nanthealth LLC (Chief Executive Officer, Director · Jun 1, 2016 – Aug 28, 2023 · Past); Abraxis BioScience Inc (Executive Chairman, Director · Nov 7, 2007 – Oct 15, 2010 · Past); APP Pharmaceuticals Inc (Director · Dec 31, 2005 – Sep 10, 2008 · Past) | Director · Since at least Sep 14, 2026 |
| Rosemary A. Crane Other companies: Certara, Inc. (Director · Since at least Jul 21, 2022); Teva Pharmaceutical Industries Limited (Independent Director · Since at least Jan 1, 2018); Tarsus Pharmaceuticals, Inc. (Director · Aug 11, 2021 – Jun 24, 2024 · Past); Catalent Inc (Director · Feb 16, 2018 – Oct 27, 2023 · Past); Unilife Corp (Director · Oct 28, 2016 – Oct 28, 2016 · Past) | Director · Sep 18, 2017 – Mar 15, 2019 · Past |
| Bruce Wendel Other companies: ImmunityBio, Inc. (Director · Since at least Dec 12, 2025); GT Biopharma, Inc. (Director · Nov 11, 2020 – Jan 27, 2023 · Past); Verastem, Inc. (Director · Jun 14, 2016 – Jun 16, 2020 · Past); Abraxis BioScience Inc (Chief Executive Officer, Director · Nov 7, 2007 – Oct 15, 2010 · Past) | Director · Since at least Oct 20, 2026 |
| Otis W. Brawley Other companies: Agilent Technologies, Inc. (Director · Since at least Nov 17, 2021); Incyte Corporation (Director · Since at least Sep 27, 2021); Lyell Immunopharma, Inc. (Director · Since at least Jun 16, 2021); Theragenics Corp (Director · May 9, 2006 – May 18, 2007 · Past) | Director · Since at least Nov 3, 2020 |
| Stephen C. Glover Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 1, 2026); ZyVersa Therapeutics, Inc. (Co-founder, Chairman, CEO, and President · Since at least Dec 12, 2022); Ambrx Biopharma Inc. (Director · May 18, 2023 – Mar 7, 2024 · Past); Insmed Incorporated (President Follow-on Biologics · Jun 22, 2007 – Mar 31, 2009 · Past) | Director · Since at least Apr 2, 2019 |
All 38 people
| Person | Seat |
|---|---|
| Albert N Marchio II Other companies: NexImmune, Inc. (See Remarks · Apr 5, 2024 – Apr 5, 2024 · Past); Fresh Tracks Therapeutics Inc. (CEO and CFO, Director · Jan 24, 2023 – Dec 28, 2023 · Past); Brickell Biotech Inc (Chief Financial Officer · Dec 1, 2020 – May 5, 2022 · Past) | Chief Accounting & Adm Officer · Sep 30, 2015 – Dec 31, 2018 · Past |
| Andrew Einhorn Other companies: Pelthos Therapeutics Inc. (Director · Since at least Dec 23, 2025); Cognition Therapeutics, Inc. (Interim CFO · Aug 12, 2022 – Aug 12, 2022 · Past); Medavail Holdings Inc (Chief Financial Officer · Oct 15, 2012 – Oct 15, 2012 · Past) | Chief Financial Officer · Sep 30, 2015 – Mar 1, 2017 · Past |
| Gregory G. Freitag Other companies: ZyVersa Therapeutics, Inc. (Principal of FreiMc · Since at least Jan 5, 2023); Pressure BioSciences, Inc. (Director · Jul 27, 2010 – Apr 5, 2012 · Past); Axogen, Inc. (Director · Jun 1, 2010 – Jun 4, 2024 · Past) | Director · Since at least Mar 15, 2019 |
| James J Loughlin Other companies: InspireMD Inc. (Director · Sep 21, 2012 – Mar 21, 2016 · Past); Celgene Corporation (Director · Jan 8, 2007 – Nov 20, 2019 · Past); Datascope Corp (Director · Jan 1, 2006 – Jan 30, 2009 · Past) | Director · Sep 30, 2015 – Jun 28, 2019 · Past |
| Mathew C Hill Other companies: Apyx Medical Corporation (Chief Financial Officer · Since at least Dec 4, 2023); STRATA Skin Sciences, Inc. (Chief Financial Officer · May 15, 2018 – Nov 13, 2020 · Past); Ep Medsystems Inc (Chief Financial Officer · Dec 12, 2006 – Dec 12, 2006 · Past) | Chief Financial Officer · Oct 18, 2021 – Jan 5, 2023 · Past |
| W Bradford Middlekauff Other companies: Amanat Acquisition Corp (Director · Since at least May 18, 2026); Tourmaline Bio Inc. (CBO, GC and Secretary · Since at least Oct 19, 2023); Immunovant, Inc. (General Counsel · Dec 18, 2019 – May 15, 2020 · Past) | Senior VP, GC and Secretary · Oct 30, 2015 – Mar 18, 2019 · Past |
| Kamil Ali-Jackson Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Dec 16, 2021); Aclaris Therapeutics, Inc. (Chief Legal Officer · Dec 15, 2020 – Jan 3, 2022 · Past) | Director · Since at least Jun 15, 2021 |
| Seth Van Voorhees Other companies: NRX Pharmaceuticals, Inc. (CHIEF FINANCIAL OFFICER · Jun 13, 2022 – Dec 16, 2022 · Past); Research Frontiers Incorporated (CFO & VP-Business Development · Dec 31, 2017 – Feb 21, 2020 · Past) | Chief Financial Officer · Jan 1, 2021 – Jun 15, 2021 · Past |
| DeLyle W Bloomquist Other companies: Rayonier Advanced Materials Inc. (President and CEO, Director · Since at least Jun 27, 2014) | Director · Mar 15, 2019 – Jun 23, 2020 · Past |
| Stephan Toutain Other companies: Interleukin Genetics Inc (Chief Commercial Officer · Aug 15, 2016 – Apr 19, 2017 · Past) | Chief Operating Officer · Since at least May 1, 2024 |
| Alpaslan Yaman | V.P., Technical Ops. & Mfg. · Sep 30, 2015 – Mar 13, 2017 · Past |
| Arnold James Banaag | Director · Since at least Sep 14, 2026 |
| Deborah Ramsdell | Director · Since at least Oct 20, 2026 |
| Frank Bedu-Addo | President/CEO, Director · Since at least Mar 15, 2019 |
| Frank Bedu-Addo | Chief Executive Officer, Director · Since at least Oct 20, 2026 |
| Gregory Conn | Chief Scientific Officer · Since at least Mar 15, 2019 |
| Herbert J Faleck | Chief Medical Officer · Sep 30, 2015 – Dec 31, 2018 · Past |
| Ilian Iliev | Director · Since at least Apr 8, 2020 |
| James Banaag | Senior Vice President Finance, Corporate Strategy, Chief Financial Officer · Since at least Oct 20, 2026 |
| Janetta Trochimiuk | Principal Accounting Officer · Since at least Mar 23, 2020 |
| John Dawson | Director · Since at least Oct 20, 2026 |
| Kirk Shepard | Chief Medical Officer · Since at least Jan 22, 2024 |
| Kurt G Conti | Director · Sep 30, 2015 – Mar 23, 2018 · Past |
| Lars Boesgaard | Chief Financial Officer · Since at least Dec 4, 2023 |
| Lauren Wood | Chief Medical Officer · Jan 5, 2023 – Jan 5, 2023 · Past |
| Renu Vaish | V.P., Global Reg. Affairs · Sep 30, 2015 – Jun 16, 2016 · Past |
| Richard Sykes | Director · Mar 15, 2019 – Jun 24, 2024 · Past |
| Spencer Brown | Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer · Since at least Jun 1, 2022 |
Log in to ask 6ix AI your own questions about PDS Biotechnology Corporation.